DE69327236D1 - Verwendung von diätetischen molkeproteinen zur behandlung von hiv seropositiven individuen - Google Patents

Verwendung von diätetischen molkeproteinen zur behandlung von hiv seropositiven individuen

Info

Publication number
DE69327236D1
DE69327236D1 DE69327236T DE69327236T DE69327236D1 DE 69327236 D1 DE69327236 D1 DE 69327236D1 DE 69327236 T DE69327236 T DE 69327236T DE 69327236 T DE69327236 T DE 69327236T DE 69327236 D1 DE69327236 D1 DE 69327236D1
Authority
DE
Germany
Prior art keywords
individues
dietetic
treating hiv
hiv seropositive
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69327236T
Other languages
English (en)
Other versions
DE69327236T2 (de
Inventor
Phil Gold
Gustavo Bounous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
2458781 CANADA INC., VAUDREUIL, QUEBEC, CA
Original Assignee
Immunotec Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotec Research Corp filed Critical Immunotec Research Corp
Application granted granted Critical
Publication of DE69327236D1 publication Critical patent/DE69327236D1/de
Publication of DE69327236T2 publication Critical patent/DE69327236T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DE69327236T 1992-04-10 1993-03-22 Verwendung von diätetischen molkeproteinen zur behandlung von hiv seropositiven individuen Expired - Lifetime DE69327236T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/866,756 US5456924A (en) 1988-12-23 1992-04-10 Method of treatment of HIV-seropositive individuals with dietary whey proteins
PCT/CA1993/000107 WO1993020831A1 (en) 1992-04-10 1993-03-22 Method of treatment of hiv-seropositive individuals with dietary whey proteins

Publications (2)

Publication Number Publication Date
DE69327236D1 true DE69327236D1 (de) 2000-01-13
DE69327236T2 DE69327236T2 (de) 2000-03-30

Family

ID=25348339

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69327236T Expired - Lifetime DE69327236T2 (de) 1992-04-10 1993-03-22 Verwendung von diätetischen molkeproteinen zur behandlung von hiv seropositiven individuen

Country Status (19)

Country Link
US (1) US5456924A (de)
EP (1) EP0634934B1 (de)
JP (1) JP2738592B2 (de)
KR (1) KR100297959B1 (de)
CN (1) CN1070371C (de)
AT (1) ATE187335T1 (de)
AU (1) AU687731B2 (de)
CA (1) CA2090186C (de)
CZ (1) CZ283386B6 (de)
DE (1) DE69327236T2 (de)
DK (1) DK0634934T3 (de)
ES (1) ES2143503T3 (de)
IL (1) IL105339A (de)
MX (1) MX9302057A (de)
NO (1) NO317795B1 (de)
NZ (1) NZ251271A (de)
TW (1) TW384223B (de)
WO (1) WO1993020831A1 (de)
ZA (1) ZA932526B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5985275A (en) * 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
CA2165937A1 (en) * 1995-05-09 1996-11-10 Immunotec Research Corporation Ltd. Process for producing an undenatured whey protein concentrate
EP0915661A4 (de) * 1996-03-06 2004-09-08 Belloch Corp I Verfahren zur behandlung flüssiger stoffe
WO1997034619A1 (en) * 1996-03-20 1997-09-25 New York Blood Center Methods of treating herpes or chlamydia
US5952009A (en) * 1996-03-20 1999-09-14 New York Blood Center Methods for preventing the transmission of or treating patients infected with herpesvirus
US6262019B1 (en) 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals
US6667063B2 (en) 1998-06-10 2003-12-23 Albert Crum Nutritional or therapeutic supplement and method
MXPA00012399A (es) * 1998-06-10 2003-07-14 Albert B Crum Complememnto nutricional profilactico y terapeutico para la creacion y mantenimiento de microflora intestinal protectora de la salud y mejoramiento del sistema inmunologico.
US6203805B1 (en) 1998-11-10 2001-03-20 Color Access, Inc. Topical compositions containing whey proteins
EP1372641A4 (de) 2001-03-05 2004-08-25 Stephen P Ernest Enterale formulierung
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
MXPA04006082A (es) 2001-12-20 2005-11-17 Technologies Biolactis Inc Matriz de proteina maleable y usos de la misma.
FR2840318B1 (fr) * 2002-05-29 2004-12-03 Quoc Kiet Pham Nouveaux sulfolipides antiretroviraux extraits de spirulines, leur procede d'obtention, les compositions les contenant et leur utilisation comme inhibiteurs de la transcriptase inverse des virus vih
FR2889067B1 (fr) * 2005-07-29 2011-11-11 Cie Laitiere Europeenne "utilisation d'une fraction proteique laitiere pour preparer une composition amincissante et/ou ameliorant la composition corporelle"
DE102006052504A1 (de) 2006-11-06 2008-05-08 Temper, Rupert Verfahren zum Herstellen eines Mittels gegen eine Infektionskrankheit
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
WO2008095276A1 (en) * 2007-02-06 2008-08-14 Cymcorp International, Inc. Novel non-toxic composition and method of using such for treating a degenerative or an immune system-related disease
US20100069288A1 (en) * 2008-09-12 2010-03-18 Wulf Droge Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival
JP2013079216A (ja) * 2011-10-04 2013-05-02 Snow Brand Milk Products Co Ltd 感覚改善剤
JP6234777B2 (ja) * 2013-10-31 2017-11-22 株式会社日立製作所 光多値送信器および光トランスポンダ
DE102014001037A1 (de) * 2014-01-25 2015-07-30 Gea Tds Gmbh Verfahren und Vorrichtung zur Reduzierung des Wachstums thermophiler Keime in Magermilch
WO2018057514A1 (en) 2016-09-23 2018-03-29 Immunotec Inc. Compositions for restoring gene expression in neuropsychiatric or neurodegenerative disorders
CA2970699A1 (en) 2017-06-14 2018-12-14 Elizabeth E. Ignowski Compositions for increasing resilience to traumatic brain injury
WO2019027974A1 (en) 2017-07-31 2019-02-07 Immunotec Inc. COMPOSITIONS AND METHODS FOR TREATING AUTISM SPECTRUM DISORDER

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA858533A (en) * 1970-12-15 Lahav Eitan Polypeptidic antibiotic substances derived from casein by fermentation
FR2565985B1 (fr) * 1984-06-19 1987-09-25 Rhone Poulenc Sante Nouvelles substances biologiquement actives obtenues a partir de la caseine bovine, leur procede de preparation et les compositions qui les contiennent
US4880626A (en) * 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US5030449A (en) * 1988-07-21 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic vaccine against AIDS virus
DE58904683D1 (de) * 1988-04-19 1993-07-22 Biotest Pharma Gmbh Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen.
CA1333471C (en) * 1988-04-29 1994-12-13 Gustavo Bounous Whey protein concentrate as food supplement
CA1338682C (en) * 1988-12-23 1996-10-29 Gustavo Bounous Biologically active undenatured whey protein concentrate as food supplement
CA2007258A1 (en) * 1989-01-11 1990-07-11 Richard L. Jackson Heparin fraction with anti-hiv activity
ATE108335T1 (de) * 1989-03-03 1994-07-15 Microgenesys Inc Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen.
AU645016B2 (en) * 1989-06-02 1994-01-06 Johns Hopkins University School Of Medicine, The Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore
CA2022394A1 (en) * 1989-08-07 1991-02-08 Allen I. Oliff Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins
ATE368112T1 (de) * 1989-12-22 2007-08-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor 40kd untereinheit und monoklonale antikörper spezifisch dafür
US5112373A (en) * 1991-06-17 1992-05-12 Hung Pham Apparatus for controlling and eliminating vapor emissions at a manicure work station

Also Published As

Publication number Publication date
DE69327236T2 (de) 2000-03-30
WO1993020831A1 (en) 1993-10-28
NO317795B1 (no) 2004-12-13
ATE187335T1 (de) 1999-12-15
TW384223B (en) 2000-03-11
DK0634934T3 (da) 2000-06-13
NZ251271A (en) 1998-05-27
IL105339A0 (en) 1993-08-18
CA2090186C (en) 1999-03-16
MX9302057A (es) 1994-07-29
AU3881293A (en) 1993-11-18
EP0634934A1 (de) 1995-01-25
KR100297959B1 (ko) 2001-10-24
CN1070371C (zh) 2001-09-05
NO943804D0 (no) 1994-10-07
CN1083704A (zh) 1994-03-16
IL105339A (en) 1998-07-15
ES2143503T3 (es) 2000-05-16
JPH07504677A (ja) 1995-05-25
US5456924A (en) 1995-10-10
KR950700752A (ko) 1995-02-20
CA2090186A1 (en) 1993-10-11
EP0634934B1 (de) 1999-12-08
ZA932526B (en) 1994-03-09
JP2738592B2 (ja) 1998-04-08
NO943804L (no) 1994-10-07
AU687731B2 (en) 1998-03-05
CZ246194A3 (en) 1995-04-12
CZ283386B6 (cs) 1998-04-15

Similar Documents

Publication Publication Date Title
DE69327236D1 (de) Verwendung von diätetischen molkeproteinen zur behandlung von hiv seropositiven individuen
Schwartz et al. Degradation of myofibrillar proteins by cathepsins B and D
Shooter Early days of the nerve growth factor proteins
Stewart II et al. Elimination of size and charge heterogeneities of human leukocyte interferons by chemical cleavage
EP0259475A4 (de) Rekombinanter menschlicher endothelzellenwachstumsfaktor.
DE3689447T2 (de) Rekombinantes Viren-Überzugsprotein assoziiert mit "Acquired Immune Deficiency Syndrome" (AIDS) und Verfahren zur Testung von AIDS.
ATE259644T1 (de) Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd
DE69721006D1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
MY102472A (en) Preparation of funtional human urokinase proteins.
Miller et al. Plasmodium falciparum: thiol status and growth in normal and glucose-6-phosphate dehydrogenase deficient human erythrocytes
FR2639958B1 (fr) Support biologique pour cultures cellulaires constitue de proteines plasmatiques coagulees par la thrombine, son utilisation pour la culture des keratinocytes, leur recuperation et leur transport a des fins d'utilisation therapeutique
ES2037669T3 (es) Un procedimiento para preparar una sustancia que se une a la trombina.
Fernandez-Sousa et al. Variation of superoxide dismutases during the development of the fruit fly Ceratitis capitata L
DK0502313T3 (da) Fremgangsmåde til sikring af tilstrækkeligt intracellulært glutathion i væv
Alter et al. Electrophoretic separation of human embryonic globin demonstrates “α-thalassemia” in human leukemia cell line K562
DE69332373T2 (de) Menschlicher epidermaler Gen-Promotor
FI881123A (fi) Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar.
Schmer et al. Induction of hypothermia in mice by semi-artificial cells containing indolyl-3-alkane α-hydroxylase
築山恭子 et al. Bovine platelet-derived factor showing mitogenic activity on bovine leukemia virus-infected lymphocytes.
NAKAJIMA The Enzymatic Degradation of Heme Proteins into Bile Pigments. XI (1) The Enzymatic Degradation of Hemoglobin-haptoglobin Complex into a Precursor of Biliverdin. I
NZ243860A (en) Increasing glutathione levels in human and animal organs using whey protein concentrate
Johnson et al. Artificial gut bioassay system- Influence of ascorbic acid on the bio-availability of iron from hydroponic spinach using human Caco-2 cell line(Abstract only)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: 2458781 CANADA INC., VAUDREUIL, QUEBEC, CA